What tirzepatide is and how it works for weight loss
Tirzepatide is a once‑weekly injectable medicine that activates two gut hormone receptors: GLP‑1 and GIP. This “dual‑agonist” action helps reduce appetite, increases satiety, slows gastric emptying, and improves insulin sensitivity. Together these effects can support clinically meaningful weight loss when combined with nutrition, activity and ongoing medical follow‑up.
- Mechanism: dual GLP‑1/GIP receptor agonist
- Main effects: less hunger, earlier fullness, lower energy intake
- Use: chronic weight management alongside lifestyle measures
What the evidence shows (SURMOUNT trials)
Multiple large, randomised trials evaluated tirzepatide for chronic weight management in adults with overweight or obesity. Average outcomes vary by dose, duration and whether participants have type 2 diabetes.
- SURMOUNT‑1 (without diabetes): Mean weight loss roughly 15–22% at 72 weeks across approved doses vs ~3% with lifestyle + placebo.
- SURMOUNT‑2 (with type 2 diabetes): Mean weight loss typically ~12–15% at 72 weeks, lower than in non‑diabetes cohorts but still clinically meaningful.
- SURMOUNT‑3: Adding tirzepatide after intensive lifestyle therapy produced additional double‑digit percentage weight loss.
- SURMOUNT‑4: Continuing therapy maintained weight loss; stopping led to partial weight regain, highlighting the need for ongoing management.
Results are averages; individual response and tolerability differ. Medical supervision and behavioural support remain important for long‑term success.
Who may consider tirzepatide for weight loss?
Eligibility is determined by a prescriber. Common criteria in clinical guidance include:
- BMI ≥30 kg/m², or BMI ≥27 kg/m² with a weight‑related condition (for example, prediabetes, type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea)
- Readiness to combine medication with nutrition, activity and follow‑up
- No relevant contraindications (see safety section)
Medicines for weight management are typically used as part of a long‑term plan. Some people qualify via type 2 diabetes care; others via obesity management criteria.
Dosing and titration overview
Dosing is individualised. A common medical approach is to start low and increase gradually to improve tolerability:
- Start: 2.5 mg once weekly
- Titration: increase by 2.5 mg every 4 weeks as tolerated (5 → 7.5 → 10 → 12.5 → 15 mg)
- Maintenance: prescriber selects the lowest effective, well‑tolerated dose
Do not change your dose without medical advice. If side effects occur during an increase, clinicians may hold or step back the dose.
Common side effects and important safety notes
Most side effects are gastrointestinal and tend to occur during dose escalation. Serious but less common risks exist and should be discussed with your prescriber.
Common
- Nausea, vomiting, diarrhoea or constipation
- Abdominal discomfort, reflux, reduced appetite
- Injection‑site reactions, fatigue, dizziness or headache
Less common but important
- Gallbladder issues (gallstones, cholecystitis)
- Pancreatitis symptoms (severe persistent abdominal pain): seek urgent care
- Kidney injury secondary to dehydration from prolonged vomiting/diarrhoea
- Hypoglycaemia risk when used with insulin or sulfonylureas
- Diabetic retinopathy changes with rapid glucose improvement (mainly in diabetes)
Contraindications and cautions
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN2: generally contraindicated due to rodent C‑cell tumour findings
- Pregnancy and breastfeeding: not recommended; discuss contraception and planning
- Severe gastrointestinal disease that may be worsened by slowed gastric emptying
- Peri‑anaesthesia: some teams advise pausing before procedures; follow your surgeon/anaesthetist’s guidance
- Oral medicines with narrow absorption windows: delayed gastric emptying may alter exposure—review with your doctor or pharmacist
Seek medical advice promptly if you experience severe abdominal pain, persistent vomiting, signs of dehydration, yellowing of the skin/eyes, or symptoms of low blood sugar.
Results timeline and what to expect
- Weeks 1–4: dose starts low; appetite often decreases; nausea is most likely during increases
- Weeks 8–16: many notice steady weight reductions as doses reach mid‑range
- Months 6–12+: average losses in trials reached double‑digit percentages with continued therapy and lifestyle measures
Weight loss usually slows over time as the body adapts. Resistance training, adequate protein, sleep and step goals help preserve lean mass and sustain progress.
Make results safer and more durable
- Protein intake: target ~1.2–1.6 g/kg/day unless advised otherwise
- Resistance training: 2–3 sessions/week to help preserve muscle
- Hydration and fibre: reduce constipation risk; consider gradual fibre increases
- Slow eating and smaller portions: support satiety and reduce nausea
- Plan for maintenance: continuing therapy or an agreed off‑ramp with behavioural strategies helps reduce regain risk
Access, brands and legality in Australia
Tirzepatide is a prescription‑only medicine in Australia. It has been approved for type 2 diabetes care and is being used in medical weight management under prescriber guidance. Brand names differ by indication and supply status; availability may vary by pharmacy and over time. Your prescriber can advise on current options, costs and whether a script is appropriate for you.
- Prescription required in Australia
- Discuss brand, supply and pharmacy fulfilment with your clinician
- Avoid grey‑market or non‑prescribed sources due to safety and legal risks
Learn more: Is Tirzepatide Legal in Australia?, Buy Tirzepatide Australia, Tirzepatide Prescription Australia, Tirzepatide Cost Australia, Mounjaro Australia Guide, Weight Loss Injections Australia, GLP‑1 Australia Guide
How tirzepatide compares with other options
Frequently asked questions
How much weight do people typically lose with tirzepatide?
Across major trials, averages ranged roughly 15–22% in people without diabetes and about 12–15% in people with type 2 diabetes over 72 weeks, alongside lifestyle measures. Individual results vary.
How fast will I notice changes?
Appetite changes often appear during the first 4–8 weeks as doses increase. Meaningful weight changes typically accumulate over several months.
What if I stop tirzepatide?
Data show partial regain is common after stopping. A maintenance plan—continuing therapy when appropriate or using behavioural strategies—helps reduce this risk.
Can tirzepatide be used without lifestyle changes?
It is intended to support, not replace, nutrition, activity and follow‑up. Combining medication with lifestyle typically improves outcomes and helps preserve muscle mass.
Who should not take tirzepatide?
People with a personal/family history of medullary thyroid carcinoma or MEN2, and those who are pregnant or breastfeeding, generally should not use it. Your doctor will review additional cautions.
Does it interact with other medicines?
Delayed gastric emptying can affect absorption of some oral medicines. Hypoglycaemia risk increases with insulin or sulfonylureas. Review your full medication list with your prescriber.
What are typical side effects?
Nausea, vomiting, diarrhoea or constipation are the most common, especially during dose increases. Serious symptoms like severe abdominal pain require urgent assessment.
Is tirzepatide the same as Mounjaro or Zepbound?
They contain the same active ingredient (tirzepatide) but are branded for different indications in some markets. Availability and approved uses differ by country and over time in Australia.
How do I access it lawfully in Australia?
Through a prescription from a qualified clinician and dispensing by a pharmacy. Avoid non‑prescribed or imported “research” versions. See our Australia‑specific access and legality pages below.
Key takeaway
Tirzepatide can produce substantial, clinically meaningful weight loss for many people when used with lifestyle changes and ongoing medical supervision. Safety screening, gradual dose titration and a long‑term maintenance plan are essential to maximise benefits and reduce risks.
Ask a question about tirzepatide
Use this form to request general guidance, discuss eligibility, or ask about lawful access in Australia. We do not sell medication; we help you understand options to discuss with a qualified prescriber.